- Open
- 1.21
- High
- 1.22
- Low
- 1.15
- Close
- 1.22
- Change
- -0.02 (-1.82%)
- Volume
- 786,532
| 20 May 2026 | 07:00:05 | Holding(s) in Company |
| 16 Apr 2026 | 12:37:09 | Holding(s) in Company |
| 31 Dec 2025 | 08:22:03 | Half-year Financial Report |
| 21 Nov 2025 | 13:38:17 | Result of AGM |
| 30 Oct 2025 | 07:30:01 | Restoration - Provexis plc |
| 11 Oct 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 13 Oct 2023 | Annual Report and Accounts (to 2023-03-31) | |
| 10 Oct 2022 | Annual Report and Accounts (to 2022-03-31) |
Provexis PLC focuses on the discovery, development, and commercialization of functional foods, medical foods, and dietary supplements, primarily through its patented Fruitflow technology. Fruitflow is a natural extract from tomatoes that has been shown to reduce the risk of aberrant blood clotting, contributing to cardiovascular health. The company generates revenue by selling Fruitflow as an ingredient to food, beverage, and dietary supplement manufacturers, and it has established partnerships with DSM Nutritional Products and BYHEALTH Co., Ltd. to expand its market reach, particularly in Europe and China.
| 20 May 2026 | 07:00:05 | Holding(s) in Company |
| 16 Apr 2026 | 12:37:09 | Holding(s) in Company |
| 31 Dec 2025 | 08:22:03 | Half-year Financial Report |
| 21 Nov 2025 | 13:38:17 | Result of AGM |
| 30 Oct 2025 | 07:30:01 | Restoration - Provexis plc |
| 11 Oct 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 13 Oct 2023 | Annual Report and Accounts (to 2023-03-31) | |
| 10 Oct 2022 | Annual Report and Accounts (to 2022-03-31) |
Provexis PLC focuses on the discovery, development, and commercialization of functional foods, medical foods, and dietary supplements, primarily through its patented Fruitflow technology. Fruitflow is a natural extract from tomatoes that has been shown to reduce the risk of aberrant blood clotting, contributing to cardiovascular health. The company generates revenue by selling Fruitflow as an ingredient to food, beverage, and dietary supplement manufacturers, and it has established partnerships with DSM Nutritional Products and BYHEALTH Co., Ltd. to expand its market reach, particularly in Europe and China.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £14.95bn | -0.1% | |
| £1.70bn | +0.0% | |
| £551m | -0.3% | |
PXSProvexis PLC | £29m | +0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £14.95bn | -0.1% | |
| £1.70bn | +0.0% | |
| £551m | -0.3% | |
PXSProvexis PLC | £29m | +0.5% |